Lilly has been under pressure in the US over its pricing for insulin products, and earlier this year launched a generic of its own Humalog brand of fast-acting insulin in an attempt to fend off ...

More than three years after approving two biosimilars referencing Sanofi’s long-acting insulin Lantus, the FDA has signed off on a rapid ... In 2023, Eli Lilly revealed a plan to cut the cost ...

Insulin was not a cure, but when used properly and combined with constant monitoring of diet and blood sugar, diabetics could now live long and active lives. Grinding pancreases for insulin at Eli ...

Sanofi is suing Lilly for alleged infringement of patents, a move that will keep the competitor's biosimilar off the market until at least mid-2016. "The marketing authorisation for this insulin ...

The FTC's negotiations with nonparty insulin-makers Eli Lilly, Novo Nordisk and Sanofi Adventis are especially sensitive, given the right jab the companies absorbed in the FTC's press release ...

“It is important that we meet people where they are to provide insulin affordability options that work for their specific circumstances,” said Andy Vicari, U.S. insulins brand leader at Lilly.